| 2006 年 | 2007 年 | 2008 年 | 2009 年 | 2010 年 |
| 2011 年 | 2012 年 | 2013 年 | 2014 年 | 2015 年 |
| 2016 年 | 2017 年 | 2018 年 | 2019 年 | 2020 年 |
| 2021 年 | 2022 年 | 2023 年 | 2024 年 |
※ 英文原著論文のみ掲載しています。
【 2023年 】
- Saeki T, Nagasawa T, Ubara Y, Taniguchi Y, Yanagita M, Nishi S, Nagata M, Yamaguchi Y, Saito T, Nakashima H, Kawano M.
Comparison of clinicopathological features between patients with and without hypocomplementemia in IgG4-related kidney disease.
Nephrol Dial Transplant. 2023; 38(4): 1053-1056. - Shimizu M, Fujii H, Kono K, Goto S, Watanabe K, Sakamoto K, Nishi S.
Clinical implication of consistently strict phosphate control for coronary and valvular calcification in incident patients undergoing hemodialysis.
J Atheroscler Thromb. 2023, ahead of print. - Fujii H, Hamano T, Tsuchiya K, Kuragano T, Joki N, Tsuruya K, Honda H, Uemura Y, Nitta K; PARAMOUNT Study Investigators.
Not baseline but time-dependent erythyropoiesis-stimulating agent responsiveness predicts cardiovascular disease in hemodialysis patients receiving epoetin beta pegol: A multicenter prospective PARAMOUNT-HD Study.
Int J Cardiol. 2023; 375: 110-118. - Goto S, Hamano T, Fujii H, Taniguchi M, Abe M, Nitta K, Nishi S.
Hypocalcemia and cardiovascular mortality in cinacalcet users.
Nephrol Dial Transplant. 2023. Online ahead of print. - Goto S, Fujii H, Mieno M, Yagisawa T, Abe M, Nitta K, Nishi S.
Survival benefit of living donor kidney transplantation in patients on hemodialysis.
Clin Exp Nephrol. 2023. Online ahead of print. - Goto S, Fujii H, Watanabe K, Shimizu M, Okamoto H, Sakamoto K, Kono K, Nishi S.
Renal protective effects of astragalus root in rat models of chronic kidney disease.
Clin Exp Nephrol. 2023;27(7):593-602. - Takiguchi R, Nishi S, Goto S, Fujii H.
Effect of Bisphosphonate and Active Vitamin D Analog on Glucocorticoid-induced Osteoporosis in Patients with IgA Nephropathy: A Retrospective Observational Study.
Kobe J Med Sci. 2023;69(1):E9-E15. - Nose Y, Fujii H, Goto S, Kono K, Okamoto H, Watanabe K, Nishi S.
Investigation of bone mineral density and the changes by enzyme replacement therapy in patients with Fabry disease.
Mol Genet Metab. 2023;139(4):107634.
